For full details on each session, please view the event guide.
8:00 am
Registration & Welcome Coffee
Humanised Mouse Models
9:15 am Chair’s Opening Remarks
9:30 am Targeting of Tumor-Specific HLA Ligands with Bispecific T Cell-Engaging Receptor (TCER™) Molecules
Synopsis
• XPRESIDENT® to exploit the repertoire of tumor-associated antigens
• Introduction into TCER™, Immatics’ TCR bispecific molecules
• TCER™ in vivo data
10:00 am Patient-Derived Experimental Models for Translational Cancer Research
Synopsis
• Overcoming drug development challenges
• Organoids: Demonstrating clinical relevance in 3D in vitro modeling
• Mouse Clinical Trials (MCTs) more closely represent the human clinical trial situation
10:30 am
Speed Networking & Morning Break
Syngeneic & PDX Models
11:30 am The Clinical IAP Antagonist ASTX660 Drives Anti-Tumor Immunity in T Cell Lymphoma
Synopsis
• ASTX660 is a potent, non-peptidomimetic antagonist of cIAP1/2 and XIAP, which has demonstrated preliminary evidence of single agent clinical activity in T cell lymphoma (TCL) patients
• To investigate the mechanism of action behind the single agent activity seen in the clinic we have used a comprehensive translational approach
via the integration of in vitro coculture systems and in vivo preclinical models with human patient data from our clinical trial
• We describe a novel role for ASTX660 as an immunomodulatory molecule, capable acting on both the innate and adaptive immune system, which could be exploited to remodel the tumor immune microenvironment
12:00 pm Considerations for the correct implementation of PDX models in Immuno-Oncology
Synopsis
• What are Patient Derived Xenograft (PDX) models?
• Traditional versus humanised PDX models
• Generation of PDX models for Immuno-Oncology?
• Applications of PDX models in Immuno-Oncology
12:30 pm SubQperior: A Superior Syngeneic Model System to Subcutaneous Tumour Models
Synopsis
• Introducing the next generation of tumour models for immuno-oncology efficacy studies overcoming common problems experienced with subcutaneous tumour implantation
12:45 pm
Networking Lunch
1:45 pm Panel Discussion: Limitations of Humanised & PDX Models
Synopsis
• How can we push these borders to include more supporting immune cells, dendritic cells, NK-cells?
• Increasing longevity; CD34 humanised hyper immune-deficient mice can increase available study lengths but also increase the cost. Is there a middle ground?
• Gaining data on persistence of cellular therapies without requiring additional mice
Next Generation Preclinical Models for IO
2:30 pm The Role of Biomarkers in the Transition from Preclinical Models to Clinical Trials in Immuno-Oncology
Synopsis
- Overview of different biomarkers and their functions
- Preclinical immuno-oncology models and biomarkers
- Brief discussion of biomarkers in immuno-oncology clinical trials
2:45 pm Targeting Kras: Pros and Cons of In Vitro Tools Versus Mouse Models
Synopsis
• Can genetic models discriminate between tumour initiating and tumour maintaining effects of KRAS?
• Can we improve the identification of biomarkers for better treatment options?
• Can genetic models be used to predict the toxicity of new KRAS-specific drugs?
3:15 pm The Next Generation of In Vivo Model for Oncology and Immuno-Oncology Drug Candidates
Synopsis
• INOVOTION’s technology opens new perspectives of in vivo screening in oncology and immuno-oncology
• Chicken embryo model has several advantages over traditional in vivo models for the discovery of cancer drugs
• Chicken embryo model fills the gap between in vitro and vivo evaluations, that’s why it’s possible to predict mouse data from chicken embryo results
3:45 pm
Afternoon Tea Break & Poster Session
4:30 pm Immune Checkpoints; Humanised Preclinical Models for Biologics’ Efficacy & MoA
Synopsis
• Exploring how model design impacts the physiological relevance and the predictability of preclinical outcomes
5:00 pm What do We Need for Next Gen Model to Enhance Predictability & Targeting?
Synopsis
• Next gen mice model vs CRISPR-based model
• How can we identify cancer resistance during preclinical stage?
• Utilizing gene editing to avoid building cell lines
5:30 pm End of Day 1
5:45 pm Poster & Drinks Reception
For full details on each session, please view the event guide.